Some studies failed to demonstrate an impact of TIMP1 tissue levels on ovarian cancer survival rates [35,36], while others described elevated pre-operative or post-chemotherapy serum levels associated with unfavorable clinical outcomes [34,37]. This evidence concerns the gene TIMP1 and ovarian cancer.